ClinicalTrials.gg
RecruitingNCT06523556Updated Nov 9, 2026

Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia

A Phase 1/2 interventional study of Axatilimab and Azacitidine in Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia and Myelodysplastic/Myeloproliferative Neoplasm, sponsored by Uma Borate. Recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Uma Borate · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Nov 9, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 179 studies in Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · United States.

Planned enrollment
42nd of 117
49 · median 36
Started
2024
the only one that year
Phase 1/2
14 of 179
1 open now
Primary completion
2027-10
later than 7 of 11 live
Registered
177th of 179
by date

Among the 179 studies in Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative with a site in United States, this one is the 42nd largest by planned enrollment of the 117 interventional ones that give a count, is the only one that started in 2024, is one of 14 in phase 1/2, reaches primary completion later than 7 of the 11 other live ones, and was the 177th registered.

Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

209 studies on the registry are indexed under Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; 8 are open to participants now.

Browse Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative studies →

Open to participants now

7 of the 179 studies in Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative studies recruiting now, 5 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 179 studies in Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative with a site in United States, or all of them as a file.
02

Study summary

This phase Ib/II trial tests the best dose of axatilimab and effectiveness of axatilimab with or without azacitidine for the treatment of patients with advanced phase myeloproliferative neoplasms (MPN), myeloproliferative neoplasm/myelodysplastic syndrome (MPN/MDS) overlap or high risk chronic myelomonocytic leukemia (CMML). Axatilimab is an antibody that is cloned from a single white blood cell that is known to be able to recognize cancer cells and block a protein on the surface of the white blood cells that may be involved in cancer cell growth. By blocking the proteins, this may slow or halt the growth of the cancer. Azacitidine is in a class of medications called antimetabolites. It works by stopping or slowing the growth of cancer cells. Giving axatilimab with or without azacitidine may be safe and effective in treating patients with advanced phase MPN, MPN/MDS overlap or high risk CMML.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the recommended phase 2 dose (RP2D) of axatilimab in relapsed or refractory patients with advanced phase MPN, MPN/MDS overlap or high-risk CMML.

II. To evaluate the overall response rate of axatilimab + azacitidine (AZA) in newly diagnosed patients with advanced phase MPN, MPN/MDS overlap or high-risk CMML using Savona response criteria.

SECONDARY OBJECTIVES:

I. Determine the safety and tolerability of axatilimab + azacitidine combination therapy in those with newly diagnosed advanced phase MPN, MPN/MDS overlap or high-risk CMML.

II. Determine the quality of life in patients receiving axatilimab + AZA using a Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF).

III. Determine the effect of axatilimab + azacitidine on symptom relief which will be measured by transfusion burden (platelet and/or packed red blood cell), time in hospital, and immune related side effects specifically reactivation of tuberculosis (TB), infusion-related reactions, hepatotoxicity, pneumonia, pyrexia, sepsis, shortness of breath (SBO), hemoptysis, periorbital edema, fatigue, and pancreatitis.

EXPLORATORY OBJECTIVES:

I. To assess the pharmacokinetics of axatilimab in combination with AZA. II. To describe the prevalence and trajectories of patients' physical activity during treatment.

III. To perform detailed correlative studies related to genetic, biochemical, and immunologic changes that occur with axatilimab in combination with AZA.

OUTLINE: This is a phase I, dose-escalation study of axatilimab followed by a phase II study.

PHASE I: Patients receive axatilimab intravenously (IV) over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At time of phase Ib completion, patients with clinical improvement may transition to phase II. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

PHASE II: Patients receive axatilimab IV over 30 minutes on days 1 and 15 and azacitidine IV over 10-40 minutes or subcutaneously (SC) on days 1-7 of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve partial response (PR) or better may continue for up to 24 total cycles. Patients who achieve less than PR receive 2 additional cycles and, if PR or better is achieved, may complete up to 24 total cycles. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

After completion of study treatment, patients are followed up at 30 days and then every 6 months for up to 24 months after last dose of study medication.

03

Conditions studied

  • Atypical Chronic Myeloid Leukemia
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic/Myeloproliferative Neoplasm
  • Recurrent Myelodysplastic/Myeloproliferative Neoplasm
  • Recurrent Myeloproliferative Neoplasm
  • Refractory Chronic Myelomonocytic Leukemia
  • Refractory Myelodysplastic/Myeloproliferative Neoplasm
  • Refractory Myeloproliferative Neoplasm
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed must be obtained prior to participation in the study
  • Age ≥ 18 years at the date of signing the informed consent form (ICF)
  • Morphologically confirmed diagnosis of the following based on 2016 World Health Organization (WHO) classification (Arber et al 2016): Phase 1b, patients with of any of the following; phase 2, patients with newly diagnosed of any of the following:

    • Chronic myelomonocytic leukemia (CMML), classified as intermediate-2, OR high-risk per the CMML Specific Prognostic Scoring System (CPSS) Molecular Model
    • Atypical chronic myelocytic leukemia (aCML)
    • MDS/MPN unclassified (MDS/MPN-U)
    • Myeloproliferative neoplasm accelerated phase (MPN-AP)
    • MPN-AP requires a previous diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or primary myelofibrosis (PMF) with intermediate-2 or high risk disease according to International Prostate Symptom Score (IPSS) as well as progression on or failure to respond to at least one .
    • Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) or MDS/MPN with SF3B1 mutation and thrombocytosis (MDS/MPN-SF3B1-T).
    • Not suitable for immediate myeloablative/intensive chemotherapy based on investigator assessment of age, comorbidities, local guidelines, institutional practice (any or all of these)
  • PHASE Ib (RELAPSE [R]/ REFRACTORY [R]): Relapse/refractory patients who have received at least two cycles of disease directed therapy (prior therapies can include hypomethylating agents [HMAs], HMA combination therapies, and other disease directed therapies)
  • PHASE II (NEWLY DIAGNOSED PHASE): Newly diagnosed patients without prior treatment, including intensive induction chemotherapy. However, previous treatment with hydroxyurea, ruxolitinib, and/or up to 2 cycles of HMAs (decitabine, azacitidine, oral decitabine [INQOVI]) is permitted
  • (ECOG) performance status of 0, 1 or 2
  • (AST) and alanine aminotransferase (ALT) ≤ 3 × (ULN)
  • Total ≤ 1.5 × ULN (except in the setting of isolated Gilbert syndrome)
  • Estimated (eGFR) ≥ 30 mL/min/1.73m\^2 (estimation based on Modification of Diet in Renal Disease [MDRD] formula, by local laboratory)
  • Patient is able to communicate with the investigator and has the ability to comply with the requirements of the study procedures
  • Women of and men, if not surgically sterilized, should use adequate from 14 days prior to study entry and until 90 days after the last follow-up visit. Adequate contraception is defined as using hormonal contraceptives or an intrauterine device combined with at least 1 of the following forms of contraception: a diaphragm or cervical cap, or a condom

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute myeloid leukemia (AML) including acute promyelocytic leukemia and extra-medullary AML based on WHO 2016 classification (Arber et al 2016)
  • Patients who are candidates for myeloablative or intensive chemotherapy treatment or who do not provide consent for this treatment
  • History of organ transplant or allogenic hematopoietic stem cell transplant
  • Participants with prior , except:

    • Participants with history of adequately treated malignancy for which no anticancer systemic therapy (namely chemotherapy, radiotherapy or surgery) is ongoing or required during the course of the study.
    • Participants who are receiving therapy such as hormone therapy are eligible. However, participants who developed therapy related neoplasms are not eligible
  • Previous known allergy/sensitivity to components of axatilimab
  • History of acute or chronic pancreatitis
  • History of myositis
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
49 participants (estimated)

Study arms

  • Experimental
    Phase I (Axatilimab)

    Patients receive axatilimab IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. At time of phase Ib completion, patients with clinical improvement may transition to phase II. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

    Biological: Axatilimab · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy

  • Experimental
    Phase II (Axatilimab and azacitidine)

    Patients receive axatilimab IV over 30 minutes on days 1 and 15 and azacitidine IV over 10-40 minutes or SC on days 1-7 of each cycle. Cycles repeat every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve PR or better may continue for up to 24 total cycles. Patients who achieve less than PR receive 2 additional cycles and, if PR or better is achieved, may complete up to 24 total cycles. Patients undergo bone marrow biopsy and aspiration and blood sample collection throughout the study.

    Biological: Axatilimab · Drug: Azacitidine · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspiration and Biopsy · Other: Survey Administration

Interventions

  • BiologicalAxatilimab

    Given IV

    Also known as: Anti-M-CSFR Monoclonal Antibody SNDX-6352, SNDX 6352, SNDX-6352, SNDX6352, UCB6352

  • Given IV or SC

    Also known as: 5 AZC, 5-AC, 5-Azacitidine, 5-Azacytidine, 5-AZC, Azacytidine, Azacytidine, 5-, Ladakamycin, Mylosar, U-18496, Vidaza

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspiration and Biopsy

    Undergo bone marrow biopsy and aspiration

  • OtherSurvey Administration

    Ancillary study

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities

    Includes hematologic and non-hematologic toxicities

    Time frame: Up to 42 days after the first dose of study medication

  2. Overall response rate

    The number of participants whose best response (according to the 2006 International Working Group response criteria) over the efficacy analysis period is a complete response or partial response will be tallied to estimate the overall response rate and provide a 95% exact confidence interval, according to the Clopper-Pearson method.

    Time frame: Up to 5 years

Secondary outcomes

  1. Incidence of adverse events

    Adverse events will be tabulated by toxicity grade and relationship with study medication and assessed by Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 30 days after end of treatment

  2. Quality of life measured by Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF)

    Will be assessed in patients receiving axatilimab + azacitidine (AZA) and will be determined using a Modified Myeloproliferative Neoplasm Symptom Assessment Form (MPNSAF) score. The MPNSAF score has a range from 0 to 100 with 100 representing the highest level of symptom severity. Descriptive statistics, means and standard deviations or medians and ranges will be applied to summarize the MPNSAF score.

    Time frame: Up to 5 years

  3. Number of platelet transfusions

    Will be assessed in patients receiving axatilimab + azacitidine and will be determined by descriptive statistics.

    Time frame: Up to 5 years

  4. Number of packed red blood cell transfusions

    Will be assessed in patients receiving axatilimab + azacitidine and will be determined by descriptive statistics.

    Time frame: Up to 5 years

  5. Time in hospital

    Will be assessed in patients receiving axatilimab + azacitidine and will be determined by descriptive statistics.

    Time frame: Up to 5 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Related links

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Oct 2027, 38 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 26, 2024
StartActual
Aug 2, 2024
Primary completionEst.
Oct 31, 2027
CompletionEst.
Oct 31, 2028
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • Oregon Health & Science University · Portland, United States
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    1 site added
    Show site
    • Oregon Health & Science University · Portland, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06523556
Lead sponsor
Uma Borate
Collaborators
Incyte Corporation
Responsible party
Uma Borate (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Jul 26, 2024
Start date
Aug 2, 2024
Primary completion
Oct 31, 2027 (estimated)
Completion
Oct 31, 2028 (estimated)
Last update
Nov 9, 2026

Study contacts

The Ohio State University Comprehensive Cancer Center
Contact
OSUCCCClinicaltrials@osumc.edu
800-293-5066
Uma M Borate, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Axatilimab

Start the discussion